Global Pharmaceutical Survey 2013-2014 – Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

Publisher Name :
Date: 19-Feb-2013
No. of pages: 149
Inquire Before Buying

Global Pharmaceutical Survey 2013-2014: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry is a new report by ICD Research that analyzes how pharmaceutical industry companies’ procurement expenditures, business strategies, and practices are set to change in 2013-2014. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable). This report gives access to category-level spending outlooks, budgets, supplier selection criteria, business challenges, and investment opportunities of leading purchase decision makers. The report also identifies the future growth of buyers and suppliers, MandA, capital expenditure, staff hiring, and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities, as well as access to information categorized by region, company type, and size.

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading global pharmaceutical industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global pharmaceutical industry. The report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies, and identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends, and business confidence within global pharmaceutical executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviours, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, ICD Research created this primary-research based report by gathering the opinions of multiple stakeholders in the value-chain of the global pharmaceutical industry.

What is the current market landscape and what is changing?

Executives from the global pharmaceutical industry anticipate an increase in levels of consolidation, with 61% of respondents projecting an increase in MandA activities in 2013.

What are the key drivers behind recent market changes?

The need for new product pipelines, new product acquisition, patent expiries, cost containment and credit availability have prompted companies to consolidate positions and look for merger and MandA acquisition.

What makes this report unique and essential to read?

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading global pharmaceutical industry executives; it provides data and analysis on buyer expenditure, procurement, and developments within the global pharmaceutical industry. The report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies, and identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends, and business confidence within global pharmaceutical industry executives. Additionally, this report also presents comparative analysis between four years of survey results (wherever applicable).

Key Features and Benefits

  • Project industry trends and revenue growth expectations in 2013, and understand business confidence to make informed business decisions.
  • Drive revenues by understanding future product investment areas and key growth regions.
  • Uncover key challenges and opportunities, and identify the key actions required to maintain and win buyer business.
  • Formulate effective sales and marketing strategies by identifying how buyer budgets are changing and the direction of spending in the future. Better promote your business by aligning your capabilities and business practices with your customer’s changing needs
  • Secure stronger customer relationships by understanding the behaviour and changing strategies of industry buyers.

Key Market Issues

  • China, Brazil and India are the important emerging markets to offer growth in 2013.
  • ‘Market uncertainty’, ‘responding to price pressure’, ‘rising competition’ and ‘regulatory changes’ are the leading business concerns for the global pharmaceutical industry in 2013.
  • Overall, for 2013, the average size of the annual procurement budget for global pharmaceutical industry buyer respondents is projected at US$127 million, against US$127 million in 2012 and US$110 million in 2011.
  • ‘Price’, ‘level of service’ and ‘existing relationship with supplier’ are considered the most important factors for supplier selection in the global pharmaceutical industry, while ‘environmental records and CSR’, ‘brand reputation’ and ‘proximity of supplier operations’ are considered the least important.
  • While 16% of buyer respondents from the global pharmaceutical industry are willing to implement e-procurement in 2013 or beyond, 32% are already in the different stages of implementation (‘partially implemented’, ‘completely implemented’, and ‘evaluation or pilot use’)

Key Highlights

  • An analysis of revenue growth expectations by senior level respondents reveals that 62% are ‘more optimistic’ about their company’s revenue growth in 2013.
  • A significant percentage of pharmaceutical manufacturing industry respondents highlighted that capital expenditure towards ‘new product development’, ‘employee training’, and ‘IT infrastructure development’ would increase in 2013.
  • The top three priorities for global pharmaceutical industry buyer respondents in 2013 are ‘new products and services’, ‘improve operational efficiency’ and ‘expand in current markets’.
  • A total of 49% of respondents from pharmaceutical manufacturing companies, 68% of respondents from CROs and CMOs companies, and 64% of respondents from pharmaceutical industry supplier companies anticipate an increase of their current workforce in 2013.
  • Survey results show that respondents from the global pharmaceutical industry identified the US to offer the highest growth potential among developed countries in 2013-2014.

Global Pharmaceutical Survey 2013-2014 – Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

Table Of Contents

1 Introduction
1.1 What is This Report About?
1.2 Definitions
1.3 Methodology
1.4 Profile of Survey Respondents: Global Pharmaceutical Industry
1.4.1 Global pharmaceutical industry: profile of buyer respondents
1.4.2 Global pharmaceutical industry: profile of supplier respondents

2 Executive Summary

3 Global Pharmaceutical Industry Dynamics
3.1 Revenue Growth Projections in the Global Pharmaceutical Industry
3.1.1 Revenue growth projections by company type
3.1.2 Revenue growth projections by region
3.1.3 Revenue growth projections by company turnover
3.1.4 Global pharmaceutical industry: revenue growth expectations by senior level respondents
3.2 Future Developments in Business Structure in the Global Pharmaceutical Industry
3.2.1 Future developments in business structure by buyers
3.2.2 Future developments in business structure by suppliers
3.2.3 Future developments in business structure by region
3.2.4 Future developments in business structure by company turnover
3.2.5 Future developments in business structure by senior level respondents
3.3 Change in Leading Company Strategies in the Global Pharmaceutical Industry
3.3.1 Change in leading company strategies by buyers
3.3.2 Change in leading company strategies by suppliers
3.3.3 Change in leading company strategies by region
3.3.4 Change in leading company strategies by company turnover
3.4 Merger and Acquisition (MandA) Activity Projections in the Global Pharmaceutical Industry
3.4.1 MandA activity projections by buyers
3.4.2 MandA activity projections by suppliers
3.4.3 MandA activity projections by region
3.4.4 MandA activity projections by company turnover
3.4.5 MandA activity projections by purchasing decision authority
3.4.6 Global pharmaceutical industry - expand abroad Vs MandA activity projections
3.5 Estimation of Capital Expenditure in the Global Pharmaceutical Industry
3.5.1 Estimation of capital expenditure by buyers
3.5.2 Estimation of capital expenditure by suppliers
3.5.3 Estimation of capital expenditure by region
3.5.4 Estimation of capital expenditure by company turnover
3.6 Planned Change in Staff Recruitment Activity in the Global Pharmaceutical Industry
3.6.1 Planned change in staff recruitment activity by buyers
3.6.2 Planned change in staff recruitment activity by suppliers
3.6.3 Planned change in staff recruitment activity by region
3.6.4 Planned change in staff recruitment activity by company turnover

4 Global Pharmaceutical Industry Market Growth Outlook
4.1 Global Pharmaceutical Industry: Demand in Emerging Markets
4.1.1 Demand in emerging markets by buyers
4.1.2 Demand in emerging markets by suppliers
4.1.3 Demand in emerging markets by region
4.1.4 Demand in emerging markets by company turnover
4.2 Global Pharmaceutical Industry - Growth Projections in Developed Countries
4.2.1 Growth projections in developed countries by buyers
4.2.2 Growth projections in developed countries by suppliers
4.2.3 Growth projections in developed countries by region
4.2.4 Growth projections in developed countries by company turnover

5 Threats and Opportunities for the Global Pharmaceutical Industry
5.1 Global Pharmaceutical Industry: Leading Business Concerns for 2013-2014
5.1.1 Leading business concerns for 2013-2014 by company type
5.1.2 Leading business concerns for 2013-2014 by region
5.1.3 Leading business concerns for 2013-2014 by company turnover
5.2 Global Pharmaceutical Industry: Key Supplier Actions to Maintain and Win Buyer Business
5.2.1 Actions to maintain and secure buyer business by buyers
5.2.2 Actions to maintain and secure buyer business by region
5.2.3 Actions to maintain and secure buyer business by company turnover
5.2.4 Actions to maintain and secure buyer business by purchasing decision authority

6 Global Pharmaceutical Industry Buyer Expenditure Activity
6.1 Annual Procurement Budgets in the Global Pharmaceutical Industry
6.1.1 Revenue growth vs. procurement budget
6.1.2 Annual procurement budgets by company type
6.1.3 Annual procurement budgets by region
6.1.4 Annual procurement budgets by company turnover
6.1.5 Annual procurement budgets by senior level respondents
6.2 Planned Change in Procurement Expenditure in the Global Pharmaceutical Industry
6.2.1 Planned change in procurement expenditure by buyer type
6.2.2 Planned change in procurement expenditure by region
6.2.3 Planned change in procurement expenditure by company turnover
6.2.4 Planned change in procurement expenditure vs. revenue growth optimism
6.2.5 Planned change in procurement expenditure vs. cost containment
6.3 Planned change in Procurement Expenditure by Product and Service Category
6.3.1 Planned change in procurement expenditure by product and service category - region
6.3.2 Planned change in procurement expenditure by product and service category - company turnover
6.4 Global Pharmaceutical Industry: Variations in Regional Supplier Prices
6.4.1 Variations in regional supplier prices by company type
6.4.2 Variations in regional supplier prices by region
6.4.3 Variations in regional supplier prices by company turnover

7 Global Pharmaceutical Industry: Procurement Behaviors and Strategies
7.1 Global Pharmaceutical Industry: Critical Success Factors for Supplier Selection
7.2 E-procurement in the Global Pharmaceutical Industry
7.2.1 E-procurement in the global pharmaceutical industry by buyer type
7.2.2 E-procurement in the global pharmaceutical industry by region
7.2.3 E-procurement in the global pharmaceutical industry by company turnover

8 Appendix
8.1 Global Pharmaceutical Industry Survey Results- Closed Questions
8.2 Methodology
8.3 Contact us
8.4 About ICD Research
8.5 Disclaimer

List Of Tables

Table 1: Global Pharmaceutical Industry Survey Respondents by Company Type, 2013
Table 2: Global Pharmaceutical Industry Buyer Respondents by Job Role (%), 2013
Table 3: Global Pharmaceutical Industry Buyer Respondents by Region (%), 2013
Table 4: Global Pharmaceutical Industry Buyer Respondents by Company Turnover (%), 2013
Table 5: Global Pharmaceutical Industry Supplier Respondents by Job Role (%), 2013
Table 6: Global Pharmaceutical Industry Supplier Respondents by Region (%), 2013
Table 7: Global Pharmaceutical Industry Supplier Respondents by Company Turnover (%), 2013
Table 8: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Table 9: Revenue Growth Optimism in the Global Pharmaceutical Industry by Buyers (%), 2010-2013
Table 10: Revenue Growth Optimism in the Global Pharmaceutical Industry by Suppliers (%), 2010-2013
Table 11: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%),2013
Table 12: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Table 13: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 14: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Table 15: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 16: Key Expected Changes in Business Structure by Turnover - Global Pharmaceutical Industry (%), 2013
Table 17: Key Expected Changes In Business Structure by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Table 18: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Table 19: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Table 20: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Table 21: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Table 22: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Table 23: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Table 24: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Table 25: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Table 26: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Table 27: Global Pharmaceutical Industry - Expand Abroad vs. MandA Activity Projections(%), 2013
Table 28: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Table 29: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Table 30: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Table 31: Global Pharmaceutical Industry - Increase in Capital Expenditure by Region (%), 2013
Table 32: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Table 33: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Table 34: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Table 35: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Table 36: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Table 37: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Table 38: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Table 39: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Table 40: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Table 41: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Table 42: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Turnover (%), 2013
Table 43: Global Pharmaceutical Industry - Leading Business Concerns (%), 2010-2013
Table 44: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Table 45: Global Pharmaceutical Industry - Leading Business Concerns by Region (%), 2013-2014
Table 46: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Table 47: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Table 48: Global Pharmaceutical Industry - Securing Buyer Business by Turnover (%), 2013
Table 49: Securing Buyer Business in the Global Pharmaceutical Industry - by Purchasing Decision Authority (%), 2013
Table 50: Annual Procurement Budgets of Global Pharmaceutical Industry Manufacturers in US$ (%), 2010-2013
Table 51: Global Pharmaceutical Industry Buyers - Increase in Revenue Growth vs. Procurement Budget (%), 2013
Table 52: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Buyer Type (%), 2013
Table 53: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Region(%), 2013
Table 54: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Turnover (%), 2013
Table 55: Global Pharmaceutical Industry - Annual Procurement Budgets in US$ by Senior Level Respondents (%), 2013
Table 56: Change in Procurement Expenditure - Global Pharmaceutical Industry Buyers (%), 2010-2013
Table 57: Global Pharmaceutical Industry - Change in Procurement Expenditure by Buyer Type (%), 2013
Table 58: Global Pharmaceutical Industry - Change in Procurement Expenditure by Region (%), 2013
Table 59: Global Pharmaceutical Industry - Change in Procurement Expenditure by Turnover (%), 2013
Table 60: Global Pharmaceutical Industry - Change in Procurement Expenditure vs. Revenue Growth (%), 2013
Table 61: Global Pharmaceutical Industry - Change in Procurement Expenditure vs. Cost Containment (%), 2013
Table 62: Future Change in Expenditure by Product and Service Category, Pharmaceutical Industry Manufacturers (%), 2013
Table 63: Future Change in Expenditure by Product and Service Category, CROs and CMOs (%), 2013
Table 64: Increase in Expenditure by Product and Service Category - Buyers by Region , 2013
Table 65: Global Pharmaceutical Industry - Variations in Regional Supplier Prices (%), 2013
Table 66: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Company Type (%), 2013
Table 67: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Region (%), 2013
Table 68: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Turnover (%), 2013
Table 69: Critical Success Factors for Supplier Selection - Global Pharmaceutical Industry Buyers, 2013
Table 70: E-Procurement - Level of Implementation in the Global Pharmaceutical Industry (%), 2013
Table 71: E-Procurement in the Global Pharmaceutical Industry: by Buyer Type(%), 2013
Table 72: E-Procurement in the Global Pharmaceutical Industry by Region (%), 2013
Table 73: E-Procurement in the Global Pharmaceutical Industry by Turnover (%), 2013
Table 74: Survey Results - Closed Questions

List of Figures

Figure 1: Revenue Growth Optimism in the Global Pharmaceutical Industry (%), 2010-2013
Figure 2: Revenue Growth Optimism in the Global Pharmaceutical Industry by Company Type (%), 2010-2013
Figure 3: Revenue Growth Optimism in the Global Pharmaceutical Industry by Region (%), 2013
Figure 4: Revenue Growth Optimism in the Global Pharmaceutical Industry by Turnover (%), 2013
Figure 5: Revenue Growth Optimism by Senior Level Respondents - Global Pharmaceutical Industry (%), 2013
Figure 6: Key Expected Changes in Business Structure by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 7: Key Expected Changes in Business Structure by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 8: Key Expected Changes in Business Structure by Region - Global Pharmaceutical Industry (%), 2013
Figure 9: Change in Leading Company Strategies by Buyers - Global Pharmaceutical Industry (%), 2013
Figure 10: Change in Leading Company Strategies by Suppliers - Global Pharmaceutical Industry (%), 2013
Figure 11: Change in Leading Company Strategies by Region - Global Pharmaceutical Industry (%), 2013
Figure 12: Change in Leading Company Strategies by Turnover - Global Pharmaceutical Industry (%), 2013
Figure 13: MandA Activity Projections - Global Pharmaceutical Industry (%), 2013
Figure 14: MandA Activity Projections - Global Pharmaceutical Manufacturers' Industry (%), 2010-2013
Figure 15: MandA Activity Projections - Global CROs and CMOs (%), 2010-2013
Figure 16: MandA Activity Projections - Global Pharmaceutical Industry Suppliers (%), 2010-2013
Figure 17: Global Pharmaceutical Industry MandA Activity Projections by Region (%), 2013
Figure 18: Global Pharmaceutical Industry MandA Activity Projections by Turnover (%), 2013
Figure 19: Global Pharmaceutical Industry MandA Activity Projections by Purchasing Decision Authority (%), 2013
Figure 20: Global Pharmaceutical Industry - Expand Abroad Vs MandA Activity Projections (%), 2013
Figure 21: Change in Capital Expenditure by Global Pharmaceutical Industry Manufacturers(%), 2013
Figure 22: Change in Capital Expenditure by Global CROs and CMOs (%), 2013
Figure 23: Change in Capital Expenditure by Pharmaceutical Industry Suppliers (%), 2013
Figure 24: Global Pharmaceutical Industry - Increase in Capital Expenditure by Turnover (%), 2013
Figure 25: Global Pharmaceutical Industry Manufacturers - Planned Change in Staff Recruitment (%), 2013
Figure 26: Global Pharmaceutical Industry Suppliers - Planned Change in Staff Recruitment Activity (%), 2013
Figure 27: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Region (%), 2013
Figure 28: Global Pharmaceutical Industry - Planned Change in Staff Recruitment Activity by Turnover (%), 2013
Figure 29: Global Pharmaceutical Industry: Top Ten Growth Regions (%), 2013
Figure 30: Global Pharmaceutical Industry: Top Five Emerging Markets, 2013
Figure 31: Global Pharmaceutical Industry Manufacturers - Demand in Emerging Markets (%), 2013
Figure 32: Global Pharmaceutical Industry CROs and CMOs - Demand in Emerging Markets (%), 2013
Figure 33: Global Pharmaceutical Industry Suppliers - Demand in Emerging Markets (%), 2013
Figure 34: Global Pharmaceutical Industry - Demand in Emerging Markets by Region (%), 2013
Figure 35: Global Pharmaceutical Industry - Demand in Emerging Markets by Turnover (%), 2013
Figure 36: Global Pharmaceutical Industry - Top Five Developed Regions by Growth (%), 2013
Figure 37: Global Pharmaceutical Manufacturers- Growth Projections in Developed Countries (%), 2013
Figure 38: Global Pharmaceutical CROs and CMOs- Growth Projections in Developed Countries (%), 2013
Figure 39: Global Pharmaceutical Industry Suppliers - Growth Projections in Developed Countries (%), 2013
Figure 40: Global Pharmaceutical Industry - Increase in Growth Projections of Developed Countries by Region (%), 2013
Figure 41: Global Pharmaceutical Industry - Top Five Leading Business Concerns, 2013
Figure 42: Global Pharmaceutical Industry - Leading Business Concerns (%), 2013
Figure 43: Global Pharmaceutical Industry - Leading Business Concerns by Company Type (%), 2013
Figure 44: Global Pharmaceutical Industry - Leading Business Concerns by Turnover (%), 2013-2014
Figure 45: Global Pharmaceutical Industry - Securing Buyer Business: Buyer vs. Supplier Responses (%), 2013
Figure 46: Actions to Secure Buyer Business, Global Pharmaceutical Industry Buyer Responses (%), 2013
Figure 47: Global Pharmaceutical Industry - Securing Buyer Business by Region (%), 2013
Figure 48: Annual Procurement Budgets of Global Pharmaceutical Industry Manufacturers in US$ (%), 2010-2013
Figure 49: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Buyer Type (%), 2013
Figure 50: Global Pharmaceutical Industry Buyers - Annual Procurement Budgets in US$ by Turnover (%), 2013
Figure 51: Global Pharmaceutical Industry - Annual Procurement Budgets in US$ by Senior Level Respondents (%), 2013
Figure 52: Change in Procurement Expenditure - Global Pharmaceutical Industry Buyers (%), 2010-2013
Figure 53: Global Pharmaceutical Industry - Change in Procurement Expenditure by Buyer Type (%), 2013
Figure 54: Global Pharmaceutical Industry - Change in Procurement Expenditure by Region (%), 2013
Figure 55: Global Pharmaceutical Industry - Change in Procurement Expenditure by Turnover (%), 2013
Figure 56: Future Change in Expenditure by Product and Service Category, Buyers , 2013
Figure 57: Future Change in Expenditure by Product and Service Category, Pharmaceutical Industry Manufacturers (%), 2013
Figure 58: Future Change in Expenditure by Product and Service Category, CROs and CMOs (%), 2013
Figure 59: Increase in Expenditure by Product and Service Category - Buyers by Turnover (%), 2013
Figure 60: Global Pharmaceutical Industry - Variations in Regional Supplier Prices (%), 2013
Figure 61: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Company Type (%), 2013
Figure 62: Global Pharmaceutical Industry - Variations in Regional Supplier Prices by Region (%), 2013
Figure 63: Critical Success Factors for Supplier Selection - Global Pharmaceutical Industry Buyers, 2013
Figure 64: E-Procurement - Level of Implementation in the Global Pharmaceutical Industry (%), 2013
Figure 65: E-Procurement in the Global Pharmaceutical Industry: by Buyer Type(%), 2013
Figure 66: E-Procurement in the Global Pharmaceutical Industry by Region (%), 2013
Figure 67: E-Procurement in the Global Pharmaceutical Industry: by Turnover (%), 2013

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Venezuela Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: Foreign currency controls and drug price cuts will continue to affect pharmaceutical companies' profitability, with the currency devaluation and high inflation exacerbating the situation. A close relationship and effective communication with the Venezuelan government are vital for the survival of domestic pharmaceutical companies. As the Venezuelan government tries to increase access to medicines, more co-ordination with drug producers to address these issues will become necessary. Hea......
  • Bahrain Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: This quarter has seen the beginning of a multi-phased plan by the National Health Regulatory Authority to significantly reduce medicine prices in the country, signalling a potential advancement towards the implementation of a unified Gulf Cooperation Council pricing system. Although less optimistic than before, our medium- and long-term outlooks for the Bahrain pharmaceutical market remain bullish. Medicines uptake will be supported by robust economic growth, in addition to the country......
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 65
    BMI View: Low health and pharmaceutical expenditures will continue to limit the attractiveness of the pharmaceutical market in Cambodia. Given such a profile, the country will present more commercial benefits to companies dealing with inexpensive generic drugs and over-the-counter products than innovative pharmaceuticals. Headline Expenditure Projections ? Pharmaceuticals: KHR828.7bn (US$210mn) in 2013 to KHR921.9bn (US$230mn) in 2014; +11.2% in local currency terms and +11.8% in US dollar terms......
  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 104
    BMI View: Overall, the Czech healthcare system is facing severe challenges as it struggles to contain budget deficits. At the same time, demand for the latest pharmaceuticals and access to healthcare services is expected to continue its steady growth trajectory, putting pressure on the state and insurers to raise premiums or redistribute funding. Following the release of pharmaceutical sales data by the SUKL, we have significantly revised down historical values for 2013 and forecasts from 2014 o......
  • Denmark Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 60
    BMI View: Although Denmark's pharmaceutical market is relatively small compared to other Western European countries, the demand for high quality healthcare will remain elevated by an increasing and ageing population. This demand could provide opportunities for private healthcare providers to expand as the government continues its restructuring and cost containment measures across the public healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: DKK20.20bn (US$3.58bn) in 2013 to D......
  • Iraq Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 75
    BMI View: The projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oildriven economic expansion, which is dependent on the government's ability to represent and appease the country's factions. Given the government's expansionary fiscal policy, spending on education, health and public services will be elevated over the coming quarters. In particular, Baghdad will seek to modernise healthcare provision, in a view to improve support to its rule. Nevertheless, there are ......
  • Lithuania Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 98
    BMI View: We expect the Lithuanian pharmaceutical market to post a five-year compound annual growth rate (CAGR) of 4.4%, rising to a value of LTL2.16bn (US$751mn) in 2018. While double-digit annual growth rates are firmly in the past, some opportunities continue to exist in light of epidemiological factors and an ageing population. The upcoming switch to the euro promises to boost purchasing power and stabilise the pharmaceutical market. However, the Lithuanian market will continue to represent ......
  • China Pharmaceutical Distribution Industry Report, 2013
    Published: 15-Apr-2014        Price: US $2400 Onwards        Pages: 110
    Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of roughly 20% in 2005-2013. As the leading players in China’s pharmaceutical distribution industry, Shanghai Pharma, Jointown and China National Accord Medicines achieved the revenue of RMB58.1 billion , RMB24.8 billion , RMB15.8 billion, respectively, in the first three quarters of 2013. In terms......
  • Carbohydrase Market by Applications (Food & Beverage, Animal Feed, Pharmaceuticals and Others), by Type (Amylases, Cellulases, and Others), Source (Microorganisms, Animals, and Plants) and by Geography – Global Trends & Forecasts to 2019
    Published: 15-Apr-2014        Price: US $4650 Onwards        Pages: 233
    Enzymes, used as processing aids, are the key differentiation factors for industrial manufacturers and a great source of product innovation and differentiation. The market for carbohydrase is expected to experience a growth of 6.6% from 2013 to 2019. The estimation is a result of regular research and developments in the industry, with widening application of carbohydrases, which are mainly involved in the conversion of carbohydrates to simple sugars. Carbohydrase has major applications within......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs